Edwards Lifesciences Q3 Earnings Beat Estimates as Sales Jump 10.5 Percent

Yes, Edwards Lifesciences beat expectations in the third quarter of 2026. The medical technology company reported adjusted earnings of 80 cents per share, up 19 percent from a year earlier, and revenue of 1.72 billion dollars, up 10.5 percent year over year. Both numbers came in above Wall Street estimates, and the company raised its full-year 2026 outlook for sales growth and adjusted earnings.

The market liked what it heard. Edwards shares jumped nearly 2.2 percent in after-hours trading after the results were released on November 4, 2026. The quarter showed strength in nearly every part of the business, from TAVR to the fast-growing mitral and tricuspid therapies.

Quick Facts

What Edwards Reported in Q3 2026

Edwards reported third-quarter 2026 results after the close of regular trading on November 4, 2026. Adjusted earnings per share came in at 80 cents, up 19 percent from a year earlier, beating the Zacks Consensus Estimate by 9.6 percent.

Revenue told a similar story. Sales rose 10.5 percent year over year to 1.72 billion dollars, and 11.2 percent at constant currency. The figure topped the consensus estimate by 2.4 percent. On the earnings call, chief executive Bernard Zovighian said the results exceeded expectations, with both the company’s businesses and its regions delivering strong, broad-based performance.

The shape of the beat matters too. Growth came from TAVR, from the newer mitral and tricuspid therapies, and from surgical products, in the United States and in international markets. That breadth is one reason management felt confident enough to raise guidance rather than simply hold it steady.

Earnings season has delivered a mix of surprises this quarter. Readers can compare the pattern in our coverage of AppLovin Q3 earnings, where a record revenue result sent the stock sharply higher. Edwards fits the stronger group, with a beat on both lines plus a higher forecast.

TAVR Remains the Engine, TMTT Is the Growth Story

Transcatheter aortic valve replacement, known as TAVR, remains the core of Edwards. TAVR sales totaled 1.24 billion dollars in the quarter, up 8 percent on a reported basis and 8.8 percent at constant currency, with similar growth in the United States and abroad, supported by rising procedure volumes and adoption of the SAPIEN 3 Ultra RESILIA platform.

The TAVR story in 2026 is as much about evidence as it is about sales. Results from the PROGRESS trial, presented at the TCT meeting and published in The New England Journal of Medicine, marked a turning point in how doctors think about moderate aortic stenosis. A large real-world study called ACTIVATE, covering more than 53,000 patients, found that moderate cases outnumber severe ones by nearly two to one, and that about 80 percent of the moderate group had at least one feature linked to higher risk. Management said the moderate patient opportunity may be at least as large as the severe one.

Policy moved in Edwards’ favor as well. During the quarter, the Centers for Medicare and Medicaid Services released an updated national coverage determination for TAVR, giving heart teams more flexibility, supporting site expansion, expanding coverage to asymptomatic patients, and creating a pathway for coverage decisions when future TAVR uses are approved.

The fastest growth came from transcatheter mitral and tricuspid therapies, known as TMTT. Sales reached 207 million dollars, up 44 percent year over year and 45.6 percent at constant currency, driven by rising procedure volumes, wider adoption of PASCAL, strong uptake of EVOQUE, and robust demand for SAPIEN M3.

Surgical sales added 264 million dollars, up 2.5 percent on a reported basis and 2.8 percent at constant currency, driven by continued adoption of RESILIA-based surgical therapies.

Margins, Cash, and the Balance Sheet

Strong sales usually help margins, and this quarter was no exception. Adjusted gross margin expanded by 80 basis points to 78.7 percent, up from 77.9 percent a year earlier, as manufacturing efficiencies and favorable foreign exchange offset the cost of scaling newer therapies.

Adjusted operating income rose 22 percent year over year to 520.5 million dollars, and adjusted operating margin expanded by 280 basis points to 30.3 percent. Selling, general and administrative expenses rose to 561 million dollars from 515 million dollars but fell as a share of sales, and research and development spending held at about 281 million dollars, or 16.4 percent of sales.

One number needs a clear explanation. GAAP diluted earnings per share were only 53 cents, well below the adjusted 80 cents, mainly because of a 220.2 million dollar impairment charge tied to an in-process research and development asset and fixed assets from an acquisition. That charge pulled GAAP operating margin down to 17.4 percent, against 30.3 percent adjusted. The impairment is a fair reminder that not every acquired asset delivers the value first expected.

The balance sheet stayed strong. As of September 30, 2026, Edwards held approximately 3.10 billion dollars in cash and cash equivalents, with total debt of about 600 million dollars. It repurchased about 700 million dollars of its own shares through the first nine months of 2026 and had roughly 1.30 billion dollars left under its buyback authorization, leaving room to invest in manufacturing and research.

The Raised 2026 Outlook, Explained

The most important part of the report may be what it says about the rest of the year. Edwards raised its 2026 constant-currency sales growth guidance to approximately 11.5 percent, up from the earlier range of 10 to 11 percent. TAVR growth guidance moved up to 9 to 9.5 percent from 8 to 9 percent, and the TMTT sales outlook increased to 780 to 790 million dollars from 760 to 780 million dollars. Surgical sales are still expected to grow at a mid-single-digit rate.

The earnings outlook moved up as well, though by a smaller step. Adjusted earnings per share guidance rose to 2.97 to 3.05 dollars from 2.95 to 3.05 dollars, so only the low end moved higher. At the midpoint, the outlook implies adjusted earnings growth of about 18 percent over the prior year. The consensus estimate for 2026 revenue stands at 6.76 billion dollars, and the consensus for adjusted earnings is 3.00 dollars.

For the fourth quarter of 2026, Edwards projects revenue of 1.67 to 1.75 billion dollars and adjusted earnings of 61 to 69 cents per share, below the third-quarter result of 80 cents. That reflects the timing of spending and a step back in operating margin toward the mid-20 percent range. The consensus for the fourth quarter is revenue of 1.70 billion dollars and earnings of 71 cents, so the company’s forecast sits slightly below analyst expectations.

A company that lifts its forecast after a strong quarter is saying the strength looks durable, not lucky. The contrast is visible elsewhere this earnings season, including in our report on Sony Q2 profit jumping 45 percent while Nintendo earnings slid, where two companies in the same broad sector told very different stories.

What Investors Should Watch Next

Management said moderate aortic stenosis approval timing and 2027 guidance were deferred to a December 4 investor conference. That event is now the next real checkpoint for anyone following the stock, because the moderate patient group could open a large new market if regulators and payers move in Edwards’ favor.

Investors should also watch how much TAVR growth comes from procedure volumes rather than market share gains. Management said future expansion should rely more on rising procedure numbers and less on taking share from rivals, which means the overall market is growing, but Edwards cannot count on share gains to keep lifting results.

The TMTT business deserves close attention too. At 207 million dollars in quarterly sales and growth above 40 percent, it is still much smaller than TAVR, but it is growing fast enough to matter. The full-year outlook of 780 to 790 million dollars implies a fourth quarter roughly flat with the third, so the next few quarters will show whether that pace can hold.

Finally, the impairment charge is worth remembering. A 220 million dollar write-down on an acquired research asset does not change the quarter’s operating story, but shareholders will want future deals to earn their keep. The same discipline applies across the market, as seen in our coverage of Toyota profit falling 19 percent while its stock posted its biggest gain in 39 years, where investors rewarded the outlook more than the headline number.

For now, the third quarter gives Edwards a solid base. Sales grew at a double-digit rate, margins expanded, cash stayed high, and guidance moved up. The fourth-quarter forecast is softer and the impairment is a blemish, but the direction of the business is clear.

Frequently Asked Questions

Did Edwards Lifesciences beat Q3 2026 earnings estimates?

Yes. Edwards reported adjusted earnings of 80 cents per share, up 19 percent year over year, beating the Zacks Consensus Estimate by 9.6 percent. Revenue of 1.72 billion dollars also topped the consensus mark by 2.4 percent.

Why did Edwards raise its 2026 outlook?

Management raised it after a strong third quarter with broad-based growth across TAVR, mitral and tricuspid therapies, and surgical products. Full-year sales growth guidance rose to about 11.5 percent at constant currency, and adjusted earnings guidance rose to 2.97 to 3.05 dollars per share.

What is TAVR and why does it matter for Edwards?

TAVR stands for transcatheter aortic valve replacement, a less invasive way to replace a narrowed aortic heart valve without open-heart surgery. It is Edwards’ largest business, with 1.24 billion dollars in third-quarter sales, and new evidence may expand its use to moderate aortic stenosis.

Why was GAAP earnings per share lower than adjusted earnings?

GAAP diluted earnings were 53 cents per share, against adjusted earnings of 80 cents, mainly because of a 220.2 million dollar impairment charge on an acquired research asset. Adjusted figures exclude that charge.

Sources

• Zacks: Edwards Q3 Earnings and Revenues Surpass Estimates, Stock Climbs
• MarketBeat: Edwards Lifesciences Q3 2026 Earnings Results and Call Transcript

Final Thoughts

Edwards Lifesciences delivered the kind of quarter investors hope for: a beat on earnings, a beat on revenue, wider margins, and a higher forecast. The heart valve business keeps growing on procedure volumes and new clinical evidence, and the mitral and tricuspid therapies are growing fast enough to become a real second engine. The fourth-quarter outlook is softer and the impairment is a reminder that growth has costs, but the main story is momentum.